Blocking interaction between SHP2 and PD‐1 denotes a novel opportunity for developing PD‐1 inhibitors

Small molecular PD‐1 inhibitors are lacking in current immuno‐oncology clinic. PD‐1/PD‐L1 antibody inhibitors currently approved for clinical usage block interaction between PD‐L1 and PD‐1 to enhance cytotoxicity of CD8(+) cytotoxic T lymphocyte (CTL). Whether other steps along the PD‐1 signaling pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Zhenzhen, Tian, Yahui, Chen, Zhipeng, Liu, Lu, Zhou, Qian, He, Jingjing, Coleman, James, Dong, Changjiang, Li, Nan, Huang, Junqi, Xu, Chenqi, Zhang, Zhimin, Gao, Song, Zhou, Penghui, Ding, Ke, Chen, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278553/
https://www.ncbi.nlm.nih.gov/pubmed/32391629
http://dx.doi.org/10.15252/emmm.201911571

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278553/
https://www.ncbi.nlm.nih.gov/pubmed/32391629
http://dx.doi.org/10.15252/emmm.201911571

Ejemplares similares